Myelofibrosis (MF) is a rare bone marrow cancer characterized by severe anemia, weakness, fatigue, and other constitutional symptoms that can severely compromise quality of life (QoL). JAK/STAT pathway inhibition is the standard of care for patients with symptomatic MF. However, certain JAK inhibitors (JAKi) can exacerbate anemia and may be unsuitable for patients dependent on red blood cell (RBC) transfusions.
Other key signaling pathways are being explored to foster development of novel therapies that can overcome challenges associated with JAKis, but clinicians need guidance on these novel therapies in order to optimize clinical outcomes. This educational initiative will survey the expanding treatment options for patients with MF, including non-JAKi agents targeting non-canonical molecular pathways.
At the end of this CME/CE activity, participants should be able to:
This educational activity is supported by an educational grant from GSK.
Physicians, PAs, nurse practitioners, nurses, and pharmacists specializing in hematology or oncology.
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process.
Dr. Mesa reports the following financial relationships: Consultant: AbbVie Inc.; Blueprint Medicines Corporation; Bristol Myers Squibb; CTI Biopharma Corp.; Genentech, Inc.; Geron; GSK; Incyte; Novartis Pharmaceuticals Corporation; Sierra Oncology, Inc.; and Telios pharmaceuticals; Editorial Advisory Board: Clinical Advances in Hematology & Oncology; Grants: Mays Cancer Center P30 Cancer Center Support Grant from National Cancer Institute (CA054174); Research Support: AbbVie Inc.; Blueprint; Bristol Myers Squibb; CTI Biopharma Corp.; Genentech, Inc.; Incyte; MorphoSys; and Sierra Oncology, Inc.
Dr. Fleischman reports the following financial relationships: Advisory Board: Incyte; PharmaEssentia Corporation; and Sierra Pharma; Speakers Bureau: CTI Biopharma Corp. and PharmaEssentia Corporation
Dr. Gerds reports the following financial relationships: Advisory Board: AbbVie Inc.; CTI Biopharma Corp.; MorphoSys; PharmaEssentia Corporation; and Sierra Oncology, Inc./GSK
The following CME Outfitters peer reviewer and staff have no financial relationships:
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Call us at (877) CME-PROS or (877) 263-7767.